In similar studies, Kohanbash and co-workers demonstrated that IDH mutations reduced the levels of CXC motif chemokine ligand 10 and STAT1, and suppressed T cell accumulation in GBM tumors.69 These effects could be reversed by IDH-C35, an inhibitor of mutant IDH1, which enhanced the effectiveness of vaccine immunotherapy. The gene discussed is IDH1; the disease is glioblastoma.